The primary aim of the UCSF-GIVI CFAR is to nurture and sustain innovative multidisciplinary HIV research at the intersections of the basic, clinical, behavioral and epidemiologic scientific disciplines. All decisions made within the Center are carefully measured against this research goal. The Center?s leadership reflects the scientific and geographic diversity of HIV research in San Francisco, and is committed to proactive rather than reactive management, which is greatly facilitated by regular weekly meetings and quarterly off-site strategic planning retreats. To catalyze multidisciplinary research, the Center has established seven scientific cores (Clinical, Behavioral Science and Epidemiology, Immunology, Virology, Pathology, Specimen Banking, and Pharmacology). Core Directors are charged with actively encouraging new investigators to join the multidisciplinary HIV research effort by taking advantage of the cutting-edge technologies and assays available within the core laboratories. Success of the scientific cores is measured by the quality of the multidisciplinary science they help to stimulate and by the publications and successful grants to which they contribute. Center activities are coordinated by an Administrative Core that maintains an electronic network to connect and inform all CFAR members, organizes scientific seminars and symposia, and implements financial systems that permit close monitoring of all CFAR funds, thereby ensuring that CFAR resources are used to maximum benefit. Such financial oversight has allowed the CFAR leadership, on occasion, to reallocate monies to support high priority research initiatives identified through strategic planning. The Developmental Core provides funding for pilot projects of young investigators and actively mentors them to help ensure their steady growth and development as young scientists. Developmental funds are also used to support strategic initiatives within the Center, when possible. The success of the UCSF-GIVI CFAR is evident in the scientific accomplishments of its investigators, its ability to galvanize fundamentally new science through its focus on innovative multidisciplinary HIV research, and the significant institutional support it receives from UCSF, the San Francisco Veterans Affairs Medical Center and The J. David Gladstone Institutes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027763-12
Application #
6612597
Study Section
Special Emphasis Panel (ZAI1-HSD-A (J1))
Program Officer
Young, Janet M
Project Start
2002-07-15
Project End
2007-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
12
Fiscal Year
2003
Total Cost
$2,543,751
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Yukl, Steven A; Kaiser, Philipp; Kim, Peggy et al. (2018) HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med 10:
Roy, Monika; Holmes, Charles; Sikazwe, Izukanji et al. (2018) Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia. Clin Infect Dis 67:1269-1277
Kiniry, Brenna E; Hunt, Peter W; Hecht, Frederick M et al. (2018) Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection. J Immunol 200:1876-1888
Jeng, Mark Y; Hull, Philip A; Fei, Mingjian et al. (2018) Metabolic reprogramming of human CD8+ memory T cells through loss of SIRT1. J Exp Med 215:51-62
Chitre, Avantika S; Kattah, Michael G; Rosli, Yenny Y et al. (2018) A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS Pathog 14:e1006806
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Leonard, Brandon; Brand, Toni M; O'Keefe, Rachel A et al. (2018) BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. Cancer Res 78:4331-4343
Wang, Chia-Ching; Thanh, Cassandra; Gibson, Erica A et al. (2018) Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv 2:3479-3482
Castillo-Mancilla, Jose R; Morrow, Mary; Boum, Yap et al. (2018) Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. J Acquir Immune Defic Syndr 77:507-513

Showing the most recent 10 out of 1541 publications